Oxford, UK; 3rd October 2018: Sensyne Health plc (LSE: SENS),the British clinical AI technology company, today announces the appointment of Professor Lionel Tarassenko CBE FREng FMedSci as Director of Research & Development and Non-Executive Director of the Board, with immediate effect. This is in addition to his current role as Chairman of Sensyne Health’s Scientific Advisory Board.
Professor Tarassenko is a world-leading expert in the application of signal processing and machine learning to medical systems, with a strong track record of translation to clinical medicine. He has been Professor of Electrical Engineering at the University of Oxford since 1997 and is the current Head of the Department of Engineering Science (Dean of Engineering).
Professor Tarassenko has been a founding director of four spin-out companies from the University of Oxford. He was made a CBE for services to engineering in the 2012 New Year’s Honours List.
Commenting on his appointment, Professor Tarassenko said:
“I am extremely pleased to join the company as Director of R&D and to join the Board. I am hugely enthusiastic about Sensyne Health’s vision to apply machine learning to anonymised NHS datasets to improve patient care and enable new discoveries in areas of immense unmet need, such as cardiovascular and cancer therapeutics.”
Prof Sir John Bell, Chairman of Sensyne Health, commented:
"Professor Tarassenko’s research is the foundation of Sensyne Health’s technology. I am delighted that our Board will benefit from his deep expertise in future.”
The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIMRules for Companies:
Full name and age: Lionel Tarassenko (aged 61)
Lionel Tarassenko holds 1,285,714 options over ordinary shares of Sensyne Health plc but does not currently hold any shares in Sensyne Health plc.
Current Directorships or Partnerships:
Oxford University Innovation Limited
Previous Directorships or Partnerships:
The Oxford Evangelical Pastorate
Oxford United Football Club Limited
No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the Aim Rules for Companies.
For more information please contact:
Sensyne Health (www.sensynehealth.com)
Lord (Paul) Drayson, Chief Executive Office
Lorimer Headley, Chief Financial Officer
Laura Steward, Head of Marketing
Peel Hunt LLP (Nominated Adviser and Broker)
Dr Christopher Golden
Consilium Strategic Communications
About Sensyne Health
Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology’.
SensyneHealth is listed on the AIM Market of the London Stock Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com